{"generic":"Radium Ra 223 Dichloride","drugs":["Radium Ra 223 Dichloride","Xofigo"],"mono":{"0":{"id":"930516-s-0","title":"Generic Names","mono":"Radium Ra 223 Dichloride"},"1":{"id":"930516-s-1","title":"Dosing and Indications","sub":[{"id":"930516-s-1-4","title":"Adult Dosing","mono":"<b>Bone metastasis, Symptomatic - Hormone refractory prostate cancer:<\/b> 50 kilobecquerel\/kg (1.35 microcurie\/kg) IV every 4 weeks for 6 cycles "},{"id":"930516-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients "},{"id":"930516-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment, mild or moderate:<\/b> no dosage adjustment required; inadequate clinical data to provide recommendation for severe renal impairment<\/li><li><b>hepatic impairment, mild:<\/b> no dosage adjustment required; inadequate clinical data to provide recommendations for moderate or severe hepatic impairment<\/li><li><b>geriatrics:<\/b> no dosage adjustment required<\/li><\/ul>"},{"id":"930516-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Bone metastasis, Symptomatic - Hormone refractory prostate cancer<br\/>"}]},"3":{"id":"930516-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930516-s-3-9","title":"Contraindications","mono":"<ul><li>pregnancy<\/li><li>women who may become pregnant<\/li><\/ul>"},{"id":"930516-s-3-10","title":"Precautions","mono":"<ul><li>myelosuppression (eg, thrombocytopenia, neutropenia, pancytopenia, leukopenia), with fatalities, has been reported; monitoring recommended; discontinuation may be necessary<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"930516-s-3-11","title":"Pregnancy Category","mono":"X (FDA)<br\/>"},{"id":"930516-s-3-12","title":"Breast Feeding","mono":"<ul><li>WHO: Avoid breastfeeding.<\/li><li>Micromedex: Infant risk cannot be ruled out.<\/li><\/ul>"}]},"5":{"id":"930516-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Peripheral edema (13%)<\/li><li><b>Hematologic:<\/b>Anemia, All grades (93%), Leukopenia, All grades (35%), Leukopenia, Grade 3 or 4 (3%), Lymphocytopenia, All grades (72%), Neutropenia, All grades (18%), Thrombocytopenia, All grades (31%)<\/li><\/ul><b>Serious<\/b><br\/><b>Hematologic:<\/b>Anemia, Grade 3 or 4 (6%), Lymphocytopenia, Grade 3 or 4 (20%), Neutropenia, Grade 3 or 4 (2%), Pancytopenia (2%), Thrombocytopenia, Grade 3 or 4 (3%)<br\/>"},"6":{"id":"930516-s-6","title":"Drug Name Info","sub":{"0":{"id":"930516-s-6-17","title":"US Trade Names","mono":"Xofigo<br\/>"},"3":{"id":"930516-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930516-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930516-s-7","title":"Mechanism Of Action","mono":"Radium Ra 223 dichloride is a radioactive agent that emits alpha particles and mimics calcium by forming complexes with the bone mineral hydroxyapatite at areas of increased bone turnover (eg, bone metastases). The alpha particles have an antitumor effect on bone metastases by breaking DNA in adjacent cells.<br\/>"},"8":{"id":"930516-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"930516-s-8-24","title":"Distribution","mono":"bone: 61% at 4 hours postinjection <br\/>"},"3":{"id":"930516-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: 13% at 48 hours<\/li><li>Renal: 2% at 48 hours<\/li><li>Total body: 63% excreted within 7 days<\/li><\/ul>"}}},"9":{"id":"930516-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>use proper handling techniques and radiation protection precautions for radiopharmaceuticals<br\/><\/li><li><b>Intravenous<\/b><br\/><ul><li>do not dilute or mix with any solutions<\/li><li>administer by slow IV injection over 1 minute; flush IV line or cannula with NS before and after injection<\/li><\/ul><\/li><\/ul>"},"10":{"id":"930516-s-10","title":"Monitoring","mono":"<ul><li>clinical and radiologic evidence of tumor regression is indicative of efficacy<\/li><li>CBC; prior to treatment initiation and before each dose; especially in patients with compromised bone marrow reserve; including differential<\/li><li>oral intake, fluid status, and urine output; carefully during therapy<\/li><\/ul>"},"11":{"id":"930516-s-11","title":"How Supplied","mono":"<b>Xofigo<\/b><br\/>Intravenous Solution: 27 uCi\/ML<br\/>"},"13":{"id":"930516-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient that use of reliable contraception to prevent pregnancy is recommended during therapy and for 6 months after therapy, including female partners.<\/li><li>Warn patient to follow precautions with bodily fluids to limit radiation exposure to others for at least 1 week after the last dose.<\/li><li>Drug may cause nausea, diarrhea, vomiting, peripheral edema, or injection site reactions.<\/li><li>Counsel patient to immediately report symptoms of bleeding or infection.<\/li><li>Advise patient to maintain adequate hydration during therapy to prevent dehydration, hypovolemia, urinary retention, or renal failure.<\/li><\/ul>"}}}